Pharmacology Flashcards
Km
Potency. It is inversely related to the affinity of the enzymes for its substrate. Km= [S] at 1/2 Vmax. The high Km, the lower the affinity.
Vmax
Efficacy. Vmax represents the maximum rate achieved by the system, at maximum (saturating) substrate concentrations.
Michaelis-Menten kinetics
Enzymatic reactions that follow a hyperbolic curve when velocity is plotted against [S]. Enzymatic reactions that exhibit a sigmoid curve usually indicate cooperative kinetics (ie hemoglobin).
Lineweaver-Burk plot
1/V plotted against 1/[S]. Y-intercept= 1/Vmax, an increase in the y-intercept = a decrease in Vmax. X-intercept= -1/Km, the closer to zero, the bigger Km is and the smaller affinity is.
Competitive reversible inhibitors
There structure resembles the substrate and binds active site of the enzyme. It can be over come by an increase in [S]. There is no effect on Vmax. It increases Km, which decreases the potency.
Competitive irreversible inhibitors
There structure resembles the substrate but does not bind the active site of the enzyme. It can not be over come by an increase in [S]. It decreases Vmax, which decreases efficacy. There is no effect on Km.
Noncompetitive inhibitors
They do not resemble substrate and do not bind the active site. It can not be overcome with an increase in [S]. It decreases Vmax, which decreases efficacy. There is no effect on Km.
Bioavailability (F)
Fraction of administered drug reaching systemic circulation unchanged. For an IV dose, F=100%. Orally, F is less than 100% due to incomplete absorption and first pass metabolism.
Volume of distribution (Vd)
Theoretical volume occupied by the total amount of drug in the body relative to its plasma concentration. Apparent Vd of plasma protein-bound drugs can be altered by liver and kidney disease (a decrease in protein binding leads to an increase in Vd). Drugs may distribute in more than one compartment. Vd=amount of drug in the body/ plasma drug concentration.
Low Vd
Usually the compartment is blood. Drug types are usually large/ charged molecules and plasma bound.
Medium Vd
Usually the compartment is ECF. Drug types are small hydrophilic molecules.
High Vd
Usually can saturate all tissues, including fat. Drug types are usually small lipophilic molecules, especially if bound to tissue protein.
Clearance (CL)
The volume of plasma cleared of drug per unit time. Clearance may be impaired with defects in cardiac, hepatic, or renal function. CL= rate of elimination of drug/ plasma drug concentration= Vd x Ke (elimination constant).
Half-life (t1/2)
The time required to change the amount of drug in the body by 1/2 during elimination (or constant infusion). Property of first order elimination. A drug infused at a constant rate takes 4-5 half-lives to reach a steady state. It takes 3.3 half lives to reach 90% of the steady state level. t1/2=(0.693 x Vd)/ CL. Time to steady state depends primarily on t1/2 and is independent of dose and dosing frequency.
Loading dose
Loading dose= (Cp x Vd)/F. Cp= target plasma concentration at steady state.
Maintenance dose
Maintenance dose= (Cp x CL x t)/ F. Cp=target dose, CL= clearance, t= dosage interval (time between doses), if not administered continuously. Cp= target plasma. In renal or liver disease, maintenance dose decreases and loading dose is usually unchanged.
Zero- order elimination
Rate of elimination is constant regardless of Cp (target plasma); constant amount of drug eliminated per unit of time. Cp decreases linearly with time. Examples of drugs include (PEA- round haped like the 0 in zero-order) Phenytoin, Ethanol, and Aspirin (at high or toxic concentrations). Capacity limited elimination.
First order elimination
Rate of elimination is directly proportional to the drug concentration (ie constant fraction of drug eliminated per unit of time). Cp decreases exponentially with time. It is flow dependent elimination.
Urine pH and drug elimination
Ionized species are trapped in urine and cleared quickly. Neutral forms can be reabsorbed. Weak acids, such as phenobarbital, methotrexate, aspirin and TCAs, get trapped in basic environment. Therefore you can treat overdoses with bicarbonate. Weak bases include amphetamines, which get trapped in acidic environments. Treat overdose with ammonium chloride.
Phase I drug metabolism
Reduction, oxidation, hydrolysis with cytochrome P-450 usually yield slightly polar, water-soluble metabolites (often still active). Geriatric patients lose phase I first.
Phase II drug metabolism
Conjugation (Glucuronidation, Acetylation, Sulfation- GAS) usually yields very polar, inactive metabolites (renally excreted). Patients who are slow acetylators have an increase in side effects from certain drugs because of a decrease in rate of metabolism.
Efficacy
The maximal effect a drug can produce. It is represented by the y-value (Vmax). It is unrelated to potency (ie efficacious drugs can have high or low potency). Partial agonists have less efficacy than full agonists.
Potency
The amount of drug needed for a given effect. An increase in potency (EC50-the concentration of a drug that gives half-maximal response)= a decrease in potency. Unrelated to efficacy (ie potent drugs can have a high or low efficacy).
Competitive antagonist
They shifts curve right (a decrease in potency, Km), no change in efficacy. Can be overcome by an increase in the concentration of agonist substrate. For example, diazepam is an agonist, while flumazenil is a competitive antagonist on the GABA receptor.
Noncompetitive antagonist
They shift the curve down, a decrease in efficacy. It cannot be overcome by an increase in agonist substrate concentration. For example, norepinephrine is an agonist, while phenoxybenzamine is a noncompetitive antagonist on alpha receptors.
Partial agonist (alone)
They act at the same site as a full agonist, but with lower than maximal effect, which is a decrease in efficacy (Vmax). Potency is an independent variable. For example, morphine is a full agonist, while buprenorphine is a partial agonistat opiod at mu-receptors.
Therapeutic index
A measurement of drug safety. TD50/ED50=median toxic dose/median effective dose= therapeutic index. Safer drugs have a higher TI value. Drugs with a lower TI value include digoxin, lithium, theophylline, and warfarin. LD50 (lethal median dose) often replaces TD50 in animal studies.
Therapeutic window
A measure of clinical drug effectiveness for a patient.
Botulinum toxin
prevents the release of acetylcholine at cholinergic terminals.
Nicotinic ACh receptors
They are ligand gated Na/K channels. Subtypes include Nn (found in autonomic ganglia) and Nm (found in neuromuscular junction).
Voluntary motor nerve
It is a somatic nerve. Lower motor neurons synapse on skeletal muscles, releasing the neurotransmitter acetylcholine, which synapse on nicotinic receptors.
Muscarinic ACh preceptos
They are G protein coupled receptors that usually act through secondary messengers. The 5 subtypes include M1, M2, M3, M4, and M5.
alpha-1 androgenic receptors
It is a Gq-protein linked 2nd messengers. It increases vascular smooth muscle contraction, increases pupillary dilator muscle contraction (mydriases), increases intestinal and bladder sphincter muscle contraction.
alpha-2 androgenic receptors
It is a Gi-protein linked 2nd messengers. It decreases sympathetic outflow, decreases insulin release, decreases lipolysis. increases platelet aggregation, and decreases aqueous humor production.
beta-1 androgenic receptors
It is a Gs-protein linked 2nd messengers. It increases heart rate, increases contractility, increases renin release, and increases lipolysis
beta-2 androgenic receptors
It is a Gs-protein linked 2nd messengers. It causes vasodilation, causes bronchodilation, increases lipolysis, increases insulin release, decreases uterine tone (tocolysis), causes ciliary muscle relaxation, and increases aqueous humor production
M1 receptors
It is a Gq-protein linked 2nd messengers. It is located in the CNS and in the enteric nervous system.
M2 receptors
It is a Gi-protein linked 2nd messengers. It decreases heart rate and contractility of atria.
M3 receptors
It is a Gq-protein linked 2nd messengers. It increases exocrine gland secretions (eg lacrimal, salivary, gastric acid), increases gut peristalsis, increases bladder contraction, causes bronchoconstriction, increases pupillary sphincter muscle contraction (miosis), causes ciliary muscle contraction (accommodation).
D1 receptors
It is a Gs-protein linked 2nd messengers. It relaxes renal vascular smooth muscle.
D2 receptors
It is a Gi-protein linked 2nd messengers. It modulates transmitter releases, especially in the brain.
H1 receptors
It is a Gq-protein linked 2nd messengers. It increases nasal and bronchial mucus production, increases vascular permeability, causes contraction of bronchioles, causes pruritus, and causes pain.
H2 receptors
It is a Gs-protein linked 2nd messengers. It increases gastric acid secretion.
V1 receptors
It is a Gq-protein linked 2nd messengers. It increases vascular smooth muscle contraction.
V2 receptors
It is a Gs-protein linked 2nd messengers. It increases H2O permeability and reabsorption in collecting tubules of the kidney (V2 found in 2 kidneys).
Gq receptors
H1, alpha1, V1, M1, M3 (HAVe 1 M&M, or 3). Binding the receptor activates phospholipase C, which cleaves PIP2 into DAG (which activates protein kinase C) and IP3 (which increases Ca, leading to smooth muscle contraction).
Gs receptors
beta1, beta2, D1, H2, V2. Gs activates adenyly cyclase, turning ATP to cAMP, which activates Protein kinase A, increasing Ca concentration (in the heart) and activating myosin light-chain kinase (in smooth muscle).
Gi receptors
M2, alpha2, D2 (MAD 2’s). Gi inhibits adenyly cyclase, reducing cAMP, inhibiting protein kinase A, decreasing Ca concentration (in the heart) and inhibiting myosin light-chain kinase (in smooth muscle).
Anticholinergic drug that inhibit choline reuptake in the presynaptic neuron
Hemicholinium
Anticholinergic drug that inhibit ACh uptake into vesicles in the presynaptic neuron
Vesamicol
Anticholinergic drug that inhibit ACh release from presynaptic neuron
Botulinum
Cholinergic drug that inhibit break down of ACh in synaptic cleft
ACh esterase inhibitors
Antiadrenergic drug that inhibits the conversion of tyrosine to DOPA in presynaptic neurons
Metryosine
Antiadrenergic drug that inhibits vesicular transport of norepinephrine, serotonin, and dopamine in presynaptic neurons
Reserpine
Antiadrenergic drug that blocks the release of noradrenaline from nerve terminals in presynaptic neurons
Bretylium
Antiadrenergic drug that reduces the release of catecholamines from nerve terminals in presynaptic neurons
Guanethidine
Adrenergic drugs that induce amphetamine and ephedrine from nerve terminals in presynaptic neurons
Amphetamine and ephedrine
Antiadrenergic drug that inhibit reuptake of catacholines into presynaptic neurons
Cocaine, TCAs, and amphetamine
Modulation of norepinephrine release from sympathetic nerve endings
It is inhibited by norepinephrine itself, acting on presynaptic alpha2- receptors
Bethanechol
Used for postoperative ileus, neurogenic ileus, and urinary retention. Direct cholinergic agonist. It activates Bowel and Bladder smooth muscle; resistant to AChE. (Bethany, call (bethanechol) me to activate your Bowels and Bladders)
Carbachol
Direct cholinergic agonist. Constricts pupil and relieves intraocular pressure in glaucoma. CARBon copy of acetylCHOLine
Methacholine
Direct cholinergic agonist. Challenge test for diagnosis of asthma. Stimulates Muscarinic receptors in airway when inhaled.
Pilocarpine
Direct cholinergic agonist. Potent stimulator of sweat, tears, and saliva. Used to treat both open angle and closed angle glaucoma. It contracts ciliary muscle of the eye (open angle glaucoma), pupillary sphincter (closed angle glaucoma). It is resistant to AChE. (You cry, drool, and sweat on your PILOw)
Donepezil
Anticholinesterases (indirect agonists). Used to treat Alzheimer disease. Increases ACh.
Galantamine
Anticholinesterases (indirect agonists). Used to treat Alzheimer disease. Increases ACh.
Rivastigmine
Anticholinesterases (indirect agonists). Used to treat Alzheimer disease. Increases ACh.
Edrophonium
Anticholinesterases (indirect agonists). Historically, used to diagnosis of myasthenia gravis (extremely short acting). Myasthenia now diagnosed by anti-AChR Ab (anti-acetylcholine receptor antibody) test. Increases ACh.
Neostigmine
Anticholinesterases (indirect agonists). Postoperative and neurogenic ileus and urinary retention, myasthenia gravis, reversal of neuromuscular junction blockade (postoperative). Increases ACh. Neo CNS= No CNS penetration.
Physostigmine
Anticholinesterases (indirect agonists). Can cause anticholinergic toxicity; it can cross blood-brain barrier into the CNS. Increases ACh. PHYsostigmine “PHYxes” atropine overdose.
Pyridostigmine
Anticholinesterases (indirect agonists). Myasthenia gravis (long acting); does not penetrate CNS. Increases ACh; increases muscle strength. PyRIDostiGMine gets RID of Myasthenia Gravis.
Toxicity of all cholinomimetic agents
Watch for exacerbation of COPD, asthma, and peptic ulcers when treating susceptible patients.
Cholinesterase inhibitor poisoning
Often due to to organophosphates, such as parathion, that irreversible inhibit AChE. Causes Diarrhea, Urination, Miosis, Bronchospasm, Bradycardia, Excitation of skeletal muscle and CNS, Lacrimation, Sweating, and Salivation. DUMBBELSS. Organophosphates are often components of insecticides; poisoning usually seen in farmers.
Treatment of cholinesterase inhibitor poisoning
Atropine (competitive inhibitor) plus pralidoxime (regenerates AChE if given early).
Atropine
Muscarinic antagonists. Targets the eye. Produces mydriasis and cycloplegia.
Homatropine
Muscarinic antagonists. Targets the eye. Produces mydriasis and cycloplegia.
Tropicamide
Muscarinic antagonists. Targets the eye. Produces mydriasis and cycloplegia.
Benztropine
Muscarinic antagonists. Targets the CNS. Treats PARKinson disease (PARK my BENZ). Also treats acute dystonia.
Glycopyrrolate
Muscarinic antagonists. Targets the GI and respiratory systems. It is used parenterally, preoperatively, to reduce airway secretions. It is also used orally, to reduce drooling and peptic ulcer.
Hyoscyamine
Muscarinic antagonists. Targets the GI system. It is used as an antispasmodics for irritable bowel syndrome.
Dicyclomine
Muscarinic antagonists. Targets the GI system. It is used as an antispasmodics for irritable bowel syndrome.
Ipratropium
Muscarinic antagonists. Targets the respiratory system. Used to treat COPD, asthma (I PRAy i can breathe soon!)
Tiotropium
Muscarinic antagonists. Targets the respiratory system. Used to treat COPD, asthma.
Oxybutynin
Muscarinic antagonists. Targets the genitourinary system. It reduces bladder spasms and urge urinary incontinence (overactive bladder).
Solifenacin
Muscarinic antagonists. Targets the genitourinary system. It reduces bladder spasms and urge urinary incontinence (overactive bladder).
Tolterodine
Muscarinic antagonists. Targets the genitourinary system. It reduces bladder spasms and urge urinary incontinence (overactive bladder).
Scopolamine
Muscarinic antagonists. Targets the CNS system. It used to treat motion sickness.
Atropine
Muscarinic antagonist. Used to treat bradycardia and for ophthalmic applications. It blocks DUMBBeLSS. Skeletal muscle and CNS excitation is mediated by nicotinic receptors. In the eyes, it increases pupil dilation and increases cycloplegia (paralysis of the ciliary muscle of the eye, resulting in a loss of accommodation). In the airway, it decreases secretions. In the stomach, it decreases acid secretions. In the gut, it decreases motility. In the bladder, it decreases urgency in cystitis.
Toxicity of atropine
Causes an increase in body temperature (due to a decrease in sweating); rapid pulse; dry mouth; dry, flushed skin; cycloplegia; constipation; disorientation. Can cause acute angle-closure glaucoma in elderly (due to mydriasis), urinary retention in men with prostatic hyperplasia, and hyperthermia in infants. Hot as a hare, dry as a bone, red as a beet, blind as a bat, and mad as a hatter. Jimson weed (Datura) causes gardener’s pupil (mydriasis due to plant alkaloids).
Tetrodotoxin
It is a highly potent toxin that binds fast voltage-gated Na channels in cardiac and nerve tissue, preventing depolarization (blocks action potential without changing resting potential). It causes nausea, diarrhea, paresthesias, weakness, dizziness, and loss of reflexes. Poisoning can result from ingestion of poorly prepared pufferfish (fugu), a delicacy in Japan. Treatment is primarily supportive.
Ciguatoxin
It causes ciguatera fish poisoning. It opens Na channels causing depolarization. Symptoms easily confused with cholinergic poisoning. Temperature-related dysesthesia (eg cold feels hot; hot feels cold) is a specific finding of ciguatera. It is caused by consumption of reef fish (eg barracuda, snapper, moray eel). Treatment is primarily supportive.
Scombroid poisoning
It is caused by consumption of dark-meat fish (eg bonito, mackerel, mahi-mahi, tuna) improperly stored at warm temperature. Bacterial histidine decarboxylase converts histidine to histamine. Histamine is not degraded by cooking. It is frequently misdiagnosed as an allergy to fish. It causes acute-onset burning sensation of the mouth, flushing of face, erythema, urticaria, pruritus, and headache. It may cause anaphylaxis-like presentation (ie bronchospasm, angioedema, hypotension). It is treated supportively with antihistamines; if needed, antianaphylactics (eg bronchodilators and epinephrine).
Albuterol
Direct sympathomimetics. Acts on beta2 more than beta1. Albuterol is used for acute asthma.
Salmeterol
Direct sympathomimetics. Acts on beta2 more than beta1. It is used for long term asthma and COPD control.
Dobutamine
Direct sympathomimetics. Acts on beta1 more than beta2 and alpha receptors. It is used to treat heart failure (inotropic- contraction more than chronotropic- HR), and cardiac stress test.
Epinephrine
Direct sympathomimetics. Acts on beta more than alpha receptors. It is used to treat anaphylaxis, asthma, open-angle glaucoma; alpha effects predominate at high doses. Significantly stronger effect at beta2 receptor than norepinephrine.